Can a simple blood test predict immunotherapy results for melanoma patients?
NCT ID NCT03348891
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study involved 60 people with advanced melanoma who were already scheduled to receive immunotherapy drugs. Researchers collected blood samples and, when possible, tumor samples before and during treatment to look for biological markers that might predict whether the treatment would work. The goal was to find clues that could help doctors choose the best therapy for each patient in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors predict which melanoma patients will benefit from specific immunotherapy combinations.
What could go wrong
This is an observational study, not a treatment trial. It may not find clear markers, and results may not change patient care directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU Claude HURIEZ
Lille, France
-
CHU Montpellier Saint-Eloi
Montpellier, France
-
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, 31059, France